CTLA4 and undifferentiated pleomorphic sarcoma: The results of several successful immunotherapy trials using an anti-programmed death-1 (PD-1) antibody and combination anti-PD-1/anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) show that a significant number of UPS patients experience a reduction in tumor size [21,23].